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A B S T R A C T
Purpose: Low bone mineral density (BMD) is associated with increased risk of fractures and mortality. We in-
vestigated if rate of BMD loss in the distal forearm over seven years predicted mortality.
Methods: 1725 postmenopausal women and 1879 men aged 50–74 who participated in the longitudinal Tromsø
Study waves 4 (1994–95) and 5 (2001−2002) were included. Cox regression models adjusted for lifestyle- and
health related variables were used to assess associations between BMD change over seven years and subsequent
mortality during up to 17 years of follow-up in participants with normal and low BMD at baseline.
Results: Baseline BMD decreased and seven-year bone loss increased with increasing age. Overall, mortality rates
were higher among those with low versus normal BMD (38 vs 19 per 1000 py in women, 56 vs 34 in men) and at
higher bone loss rates (rate ratio high:low = 1.2 in women, 1.7 in men). BMD change was associated with
increased mortality only in men with normal baseline BMD. In this group, men with a BMD loss of > 4% had
significantly higher mortality (HR 1.50, 95% CI 1.21, 1.87) than men with increased or unchanged BMD. BMD
change was not significantly associated with increased mortality in women or in men with low BMD at baseline.
Conclusions: BMD loss in the distal forearm was associated with increased mortality in men with normal BMD at
baseline, but not in women. We found no clear association between BMD loss and mortality in those with low
BMD at baseline.
1. Introduction
Declining bone mineral density (BMD g/cm2) is a part of the ageing
process in both women and men. Peak bone mass is the point at which
bone density is highest during the life span and is usually reached
during the end of the second or beginning of the third decade [1–3].
The point of peak bone mass and the rate of decline can vary greatly
from person to person, depending on both genetics and numerous
health- and lifestyle-related variables such as level of physical activity,
BMI, smoking habits, presence of various diseases and use of medica-
tion [4–8], resulting in some people developing osteoporosis while
others do not. Osteoporosis is a systemic skeletal disease characterized
by low bone mass and microarchitectural deterioration causing
increased bone fragility and susceptibility to fracture [9]. The condition
is widespread in older populations globally, with an estimated pre-
valence of 22.1% in women and 6.6% in men aged 50+ and 47.2% in
women and 16.6% in men aged 80+ [10]. Osteoporosis poses a huge
public health burden through fragility fractures [11,12] and subsequent
pain, disability, medical expenses, reduced quality of life and increased
mortality [13–15], especially following hip fractures [16–21]. In a re-
cent study, we found that low BMD in the distal forearm categorized as
osteopenia and osteoporosis were both associated with increased mor-
tality, and the association was only slightly attenuated by taking os-
teoporotic fractures into account [22]. This may suggest that vulner-
ability in people with low BMD comprises more than an increased
fracture risk.
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In women, most of the bone loss occurs in the late perimenopause
and beginning of the postmenopausal period [23,24]. In men, however,
BMD loss varies less in older age and BMD levels in the distal forearm
have been found to decrease consistently from around the age of
50 years [24–26].
Repeated measurements give information, not only about the up-
dated BMD status, but also about the rate of BMD change which might
help identification of individuals with a higher risk of developing os-
teoporosis and a higher mortality. While several recent prospective
studies continue to confirm the association between BMD and mortality
in general populations and within disease categories [15,22,27–32], it
is uncertain whether rate of bone loss per se also contributes to pre-
dicting mortality. Some studies have indicated that the rate of bone loss
in weight bearing sites such as hip, spine and calcaneus is positively
associated with mortality [33–35], but these studies included relatively
old populations with a mean age of > 70 years at baseline. One study
[33] only included women and had a short mean follow-up of only
3.2 years and the most recent study found the association between rate
of BMD loss and mortality to be most pronounced in men [35]. To the
best of our knowledge, no studies have investigated the association
between the rate of bone loss in non-weight bearing sites, such as the
forearm, and mortality in a general population. While BMD loss at
weight bearing sites can be a result of declining physical function and
limited ability to stay active [36], BMD in non-weight bearing sites
might be less sensitive to such changes in everyday load and therefore
yield additional insight to any association between rate of BMD loss and
mortality. BMD loss might also be more critical in regards of mortality
for persons with already established osteoporosis due to marginal bone
reserve and inherent structural integrity. If so, this is important to
consider when discussing treatment strategies for patients with low
BMD. The population-based Tromsø Study in Northern Norway per-
formed bone densitometry in the distal forearm in men and women in
1994–95 and retested the same participants seven years later in
2001–02 [25]. We investigated whether the seven-year rate of bone loss
in the distal forearm predicted mortality and whether the association
between BMD loss and mortality varied between those with normal
BMD, osteopenia or osteoporosis at baseline.
2. Method
2.1. Study population
The Tromsø Study, initiated in 1974, is a longitudinal, population
based, multi-purpose study focusing on lifestyle-related diseases and
their risk factors [37]. The current study population comprised in-
dividuals who participated in both the fourth (Tromsø 4) and fifth
(Tromsø 5) wave, conducted in 1994–95 and 2001–02, respectively.
Tromsø 4 included distal forearm bone densitometry in a subgroup as
part of additional testing offered to all women aged 50–74 years, all
men aged 55–74 year and random subsamples (10–15%) of younger
(24–55 years) and older participants (74–85 years). All participants in
Tromsø 4 who were still alive and residing in the area were invited to
participate in Tromsø 5. The current analyses are restricted to partici-
pants aged 50–74 years at the time of Tromsø 4 and women who had
undergone menopause more than five years prior to Tromsø 4, hence
aged 57–81 years at Tromsø 5. The attendance rate in Tromsø 4 was
76% among men and 79% among women in this age group. Of the
Tromsø 4 participants who were re-invited to Tromsø 5, 4936 (86% of
those in the pertinent age range who were still alive and residing in
Tromsø county) attended the additional testing in Tromsø 5 [38]. After
exclusion of participants with missing values for potential health- and
lifestyle related confounders (see covariate section), the final study
population for analysis consisted of 3604 participants, 1725 women
with a mean age of 62.4 years (SD = 6.2) and 1879 men with a mean
age of 61.7 years (SD = 6.0) per 31st December 1994. See Fig. 1 for
flow chart of inclusion and exclusion of participants.
2.2. Assessment of bone mineral density (BMD)
BMD was measured using single X-ray absorptiometry (SXA) on the
non-dominant forearm at the distal and ultra-distal sites with two SXA
devices (DTX-100; Osteometer MediTech, Inc., Hawthorne, California).
The same devices were used in both Tromsø 4 and Tromsø 5. The
dominant arm was used for measurement in 1% of the participants
when the non-dominant arm was ineligible due to wounds, plaster casts
etc. The testing procedure and quality assessment is described in detail
by Berntsen et al. and Emaus et al. [38,39]. An individual BMD change
should be > 2% (distal) or 3% (ultra-distal) before it can be reliably
detected by two separate measurements [40]. We have previously used
the distal measurements, including both radius and ulna, from 1994 in
analyses on BMD and mortality [22] and continued to do so in this
study for the sake of comparability. Least significant change (LSC) was
therefore defined as > 2% in our analyses.
2.3. Reference values for low BMD (osteopenia and osteoporosis)
Gender specific internal BMD reference values were created for
osteopenia and osteoporosis. These were based on BMD values corre-
sponding to 1 and 2.5 SDs below the mean BMD of healthy men and
women aged 24–39 years in the Tromsø 4 densitometry data [22]. The
mean BMD-value of the reference groups were 0.471 g/cm2
(SD = 0.043) in women and 0.575 g/cm2 (SD = 0.045) in men,
yielding threshold values for osteopenia and osteoporosis of 0.428 g/
cm2 and 0.364 g/cm2 in women and 0.531 g/cm2 and 0.464 g/cm2 in
men. Participants with osteopenia or osteoporosis were placed in the
category “Low BMD” in the analyses. Any BMD value above the
threshold for osteopenia was categorized as “Normal”.
2.4. Ascertainment of deaths
Data on each participant was linked to the Norwegian Cause of
Death Registry and to the National Registry for assessment of death and
emigration by the means of the unique personal identification number.
Participants were followed from the Tromsø 5 study wave in 2001 until
emigration, death or October 6th 2018, whichever occurred first.
2.5. Covariates
The following lifestyle and health related variables from Tromsø 4
were considered to be potential confounders: BMI was calculated as
weight in kilograms divided by height in meters squared (kg/m2). Both
height and weight were objectively measured by trained personnel.
Self-reported smoking habits were categorized as “current”, “previous”
or “never-smoker”. Education level based on years of completed edu-
cation was grouped into five levels: “7-10 years primary/secondary
school”, “Technical school, middle school, vocational school, 1-2 years
senior high school”, “High school diploma (3-4 years)”, “College/uni-
versity, less than 4 years” and “college/university 4 or more years”.
Self-reported level of activity, reported as number of hours spent on
light physical activity (not sweating or out of breath) and hard physical
activity (sweating and/or out of breath) during a typical week, was
categorized in four groups for each variable: “none”, “less than one”,
“one to two”, “three or more”. Self-reported chronic diseases were re-
gistered by answering “yes” or “no” following questions about whether
they have had or currently have the following diseases: stroke, myo-
cardial infarction, angina, diabetes or asthma. Self-perceived health
was described in the categories: “poor”, “not so good”, “good” and
“very good”. The following variables from Tromsø 5 were also included:
BMI-change between Tromsø 4 and Tromsø 5 and use of anti-osteo-
porosis drugs (AOD) within ATC-category “M05B” (drugs affecting
bone structure and mineralization). In women, we also adjusted for
hormone replacement therapy (HRT), reported as “current”,” previous”
or “never” in Tromsø 5, cessation of HRT between Tromsø 4 and
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Tromsø 5 and years since menopause. The onset of menopause was self-
reported as age when menstruation ceased, given amenorrhea for at
least 12 months.
2.6. Statistical analysis
Separate analyses were conducted for women and men with gender-
specific cut-off values for “Normal BMD” and “Low BMD” based on T-
scores above or below −1 and adjustment for menopause and HRT only
in women. Participants were divided into two groups: “Normal BMD” or
“Low BMD” based on their distal forearm BMD at baseline. These
groups were further divided into three groups of BMD change over the
period: 1: positive or unchanged (≥−2%), 2: 1× LSC to 2× LSC bone
loss (−2% to −4%), or 3: > 2× LSC bone loss (< −4%), in order to
allow for comparison between the upper and lower extremes of the
distribution of BMD change. A set of Cox regression models were used
to estimate the association between seven-year BMD change and mor-
tality with a maximum follow-up time of 17 years. First, within each of
the two baseline BMD groups, BMD change over the seven-year period
categorized by LSC were regressed against mortality, using group 1
(positive or unchanged) as reference category. Attained age defined the
time scale in the Cox models, thereby effectively adjusting for age, and
we successively adjusted for potential confounders assessed at baseline:
BMD, BMI, level of physical activity, smoking habits, category of
completed education, self-rated health, self-reports of chronic diseases
and follow-up information on use of AODs and BMI change between
Tromsø 4 and Tromsø 5. In women, we also adjusted for years since
menopause and use/cessation of HRT at follow-up. Secondly, within the
two baseline BMD groups, mortality across the distribution of percen-
tage BMD change was assessed by modelling continuous BMD change as
restricted cubic splines with three knots, using default knot location. In
the analysis with splines, outliers defined as BMD change exceeding
+5% or −15% were removed to avoid a large influence by a few ex-
treme values, excluding 211 participants in total. Outliers were not
excluded in the Cox models on LSC of BMD change because they were
not expected to influence the models as much. Statistical significance
was defined by an alpha level of 0.05 and statistical analyses were
carried out with Stata/SE 15.
3. Results
Mean age at baseline was 62.4 (SD 6.2) in women and 61.7 (SD 6.0)
in men and BMD change during follow-up was −4.8% (SD 6.7) and
−3.2% (SD 3.9) respectively. Complete demographics for our study
Fig. 1. Flow chart describing inclusion and exclusion of participants.
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population, those who only attended Tromsø 4 and the complete po-
pulation who attended both Tromsø 4 and Tromsø 5, (including those
excluded from our study sample) is presented in Table 1. Table 2 shows
mean BMD at baseline and follow-up, as well as BMD changes and
number of deaths in 5-year age groups in women and men. Out of 3604
participants, 1363 had unchanged or increased BMD values at the
follow-up measurement based on the LSC definition of 2% (548 women
and 815 men). A higher proportion of these women reported use of HRT
(15.3%) or AODs (5.7%) at the second measurement than those with a
decrease in BMD (5.5% and 3.1%). Only 5 men (0.3%) in total reported
currently using AODs in 2001, of whom two men had unchanged/
increased BMD. BMD was strongly inversely correlated with age
(Table 2). Mean BMD loss over seven years was similar across age
groups in women, while it increased with advancing age in men. Per-
cent BMD loss increased with age in both women and men (Table 2).
Those with low BMD at baseline were oldest and had the highest
mortality rates (Table 3). Overall, mortality rates were highest in the
groups with the largest bone loss in both women and men, but mortality
rates in women varied less between groups of BMD change than in men.
The absolute differences in mortality between the upper and lower
groups of BMD change were similar in both baseline BMD groups (3–4
per 1000 person years) but larger within the group with normal
Table 1
Descriptive baseline characteristics (first visit, Tromsø 4) presented as mean values with standard deviations (SD) for continuous variables and number of participants
(N) with rates (%) for categorical variables. Use of anti-osteoporotic drugs (AODs) and hormone replacement therapy (HRT) is described at second visit (Tromsø 5).
Characteristics described for women and men separately in our study sample, in those who only participated in Tromsø 4 and in those who participated in both
Tromsø 4 and 5 (including those who did not meet our inclusion criteria).
Variables included in analyses Women Men
Our study Only Tromsø 4 Tromsø 4 + Tromsø 5 Our study Only Tromsø 4 Tromsø 4 + Tromsø 5
(n = 1725) (n = 941) (n = 2973) (n = 1879) (n = 855) (n = 1963)
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Age (T4) 62.4 (6.2) 62.7 (7.6) 59.9 (7.0) 61.7 (6.0) 64.3 (6.5) 61.8 (6.1)
BMI (T4) 26.1 (4.2) 26.3 (4.9) 26.0 (4.2) 26.1 (3.2) 26.0 (3.7) 26.1 (3.2)
BMI change (T4 ➔ T5) 0.9 (2.2) – 0.9 (2.2) 0.6 (1.6) – 0.6 (1.7)
BMD, g/cm2 (T4) 0.392 (0.065) 0.390 (0.072) 0.408 (0.067) 0.541 (0.063) 0.519 (0.070) 0.540 (0.063)
BMD change, % (T4 ➔ T5) −4.8 (6.7) – −5.8 (6.6) −3.2 (3.9) – −3.2 (4.0)
Years since menopause (T4) 21.9 (6.7) 19.4 (8.8) 17.9 (8.8) – – –
Menopause age 47.7 (4.9) 48.3 (4.8) 48.4 (4.7) – – –
N (%) N (%) N (%) N (%) N (%) N (%)
Use AODs (T5) 68 (3.9) – 96 (3.2) 5 (0.3) – 5 (0.3)
Use HRT (T5)
Never 1369 (79.4) 912 (96.9) 2325 (78.2) – – –
Previous 207 (12.0) 15 (1.6) 350 (11.8) – – –
Current 149 (8.6) 14 (1.5) 298 (10.0) – – –
Smoking (T4)
Never 775 (44.9) 357 (38.0) 1332 (44.8) 390 (20.8) 127 (14.9) 401 (20.4)
Previous 483 (28.0) 238 (25.3) 803 (27.0) 970 (51.6) 398 (46.5) 1016 (51.8)
Current 467 (27.1) 344 (36.6) 836 (28.1) 519 (27.6) 330 (38.6) 545 (27.8)
Education (T4)
7–10 years prim./sec. School 1083 (62.8) 602 (64.7) 1773 (60.0) 865 (46.0) 426 (50.1) 903 (4.6)
[…]/ 1–2 years senior high school 388 (22.5) 195 (21.0) 673 (22.8) 553 (29.4) 244 (28.7) 576 (29.4)
High school diploma (3–4 years) 47 (2.7) 21 (2.3) 86 (2.9) 74 (3.9) 37 (4.4) 78 (4.0)
College/University < 4 years 114 (6.6) 68 (7.3) 222 (7.5) 238 (12.7) 83 (9.8) 247 (12.6)
College/University 4 years or more 93 (5.4) 44 (4.7) 200 (6.8) 149 (7.9) 60 (7.1) 152 (7.8)
Diseases (T4)
Stroke 25 (1.4) 32 (3.4) 40 (1.3) 44 (2.3) 47 (5.5) 48 (2.5)
Angina 108 (6.3) 97 (10.3) 162 (5.5) 199 (10.6) 139 (16.3) 211 (10.8)
Myocardial infarction 28 (1.6) 60 (6.4) 50 (1.7) 162 (8.6) 120 (14.0) 171 (8.7)
Diabetes 39 (2.3) 46 (4.9) 65 (2.2) 44 (2.3) 52 (6.1) 49 (2.5)
Asthma 156 (9.0) 99 (10.5) 234 (7.9) 123 (6.5) 70 (8.2) 132 (6.8)
Light physical activity (T4)
None 203 (11.8) 187 (19.9) 354 (11.9) 200 (10.6) 144 (17.0) 212 (10.9)
< 1 time per week 196 (11.4) 129 (13.7) 368 (12.4) 230 (12.2) 116 (13.7) 238 (12.2)
1–2 times per week 584 (33.9) 295 (31.4) 1013 (34.1) 554 (29.5) 236 (27.8) 582 (29.8)
3 times per week or more 742 (43.0) 328 (34.9) 1233 (41.5) 895 (47.6) 352 (41.5) 921 (47.2)
Hard physical activity (T4)
None 1258 (72.9) 748 (80.6) 2066 (70.2) 999 (53.2) 550 (65.4) 1032 (53.0)
< 1 time per week 212 (12.3) 83 (8.9) 416 (14.1) 331 (17.6) 101 (12.0) 346 (17.8)
1–2 times per week 179 (10.4) 67 (7.2) 332 (11.3) 341 (18.1) 119 (14.1) 353 (18.1)
3 times per week or more 76 (4.4) 30 (3.2) 131 (4.4) 208 (11.1) 71 (8.4) 215 (11.0)
Self-reported health (T4)
Poor 37 (2.1) 65 (6.9) 65 (2.2) 46 (2.4) 45 (5.3) 50 (2.5)
Not so good 815 (47.2) 484 (51.5) 1333 (44.9) 688 (36.6) 395 (46.3) 722 (36.8)
Good 791 (45.9) 342 (36.4) 1396 (47.0) 1027 (54.7) 378 (44.3) 1068 (54.5)
Very good 82 (4.8) 48 (5.1) 175 (5.9) 118 (6.3) 35 (4.1) 121 (6.2)
BMD group (T4)
Normal BMD 531 (30.8) 307 (32.6) 1230 (41.4) 1101 (58.6) 395 (46.2) 1148 (58.5)
Osteopenia 624 (36.2) 284 (30.2) 986 (33.2) 571 (30.4) 282 (33.0) 593 (30.2)
Osteoporosis 570 (33.0) 350 (37.2) 757 (25.5) 207 (11.0) 178 (20.8) 222 (11.3)
Deaths 756 (43.8) 621 (66.0) 1094 (36.8) 1001 (53.3) 696 (81.4) 1058 (53.9)
T4 = Tromsø 4. T5 = Tromsø 5. BMI=Bone mineral density of distal forearm. AOD = Anti-osteoporotic drug. HRT = Hormone replacement therapy.
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baseline BMD in men compared to those with low baseline BMD (23 vs
13). However, the mortality rate ratio in group 3 to group 1 of BMD
change was clearly higher in the group with normal BMD at baseline in
both genders, although most pronounced in men, (1.25 in women and
1.85 in men) compared to the group with low BMD at baseline (1.10 in
women and 1.28 in men). Both women and men with a large BMD loss
(group 3) in the distal forearm between Tromsø 4 and Tromsø 5 had the
lowest BMD total hip values at Tromsø 5. The men with unchanged or
increased BMD in the forearm (group 1) had the highest total hip BMD
in both baseline BMD groups while in women, those with a low baseline
BMD who experienced a BMD loss in the distal forearm between −2
and −4% (group 2) had the highest hip BMD.
HRs with 95% CI in successively adjusted Cox regression models in
women and men with normal and low BMD at baseline are shown in
Table 4. No associations were found between BMD loss and mortality in
the fully adjusted models for women, regardless of baseline BMD group.
Among men with normal BMD at baseline, those with a large bone loss
had significantly higher mortality compared with those with unchanged
or increased BMD (group 3 vs group 1: HR = 1.50, 95% CI 1.21, 1.87).
Differences in mortality between BMD change groups were not statis-
tically significant among men with low BMD levels at baseline
(Table 4).
Mortality HRs with 95% confidence intervals across the range of
continuous percent BMD change, based on cubic splines, are shown in
Fig. 2. In women, no statistically significant associations were observed
between BMD change and mortality in either category of baseline BMD.
In men, CIs exceeded HR = 1.00 in the group with normal BMD at
baseline, indicating a statistically significant increase in mortality with
increasing bone loss for this group.
Table 2
Mean BMD at baseline (Tromsø 4, 1994/95) and follow-up (Tromsø 5, 2001/02), changes in BMD between baseline and follow-up and number of deaths in 5-year age
groups for women and men separately.








Women: 62.4 (6.2) 1725 0.392 (0.065) 0.373 (0.067) −0.019 (−4.8) 756 (43.8)
50–54 195 0.438 (0.053) 0.418 (0.059) −0.020 (−4.5) 32 (16.4)
55–59 411 0.418 (0.054) 0.399 (0.057) −0.018 (−4.4) 88 (21.4)
60–64 443 0.396 (0.059) 0.378 (0.062) −0.018 (−4.6) 162 (36.6)
65–69 412 0.368 (0.061) 0.347 (0.063) −0.021 (−5.6) 252 (61.2)
70–74 264 0.350 (0.065) 0.332 (0.063) −0.018 (−4.9) 222 (84.1)
Men: 61.7 (6.0) 1879 0.541 (0.063) 0.524 (0.068) −0.017 (−3.2) 1001 (53.3)
50–54 175 0.566 (0.048) 0.556 (0.050) −0.010 (−1.8) 31 (17.7)
55–59 582 0.556 (0.054) 0.543 (0.057) −0.012 (−2.3) 180 (30.9)
60–64 500 0.543 (0.060) 0.526 (0.066) −0.017 (−3.3) 270 (54.0)
65–69 372 0.524 (0.068) 0.503 (0.072) −0.021 (−4.1) 287 (77.2)
70–74 250 0.509 (0.070) 0.485 (0.075) −0.024 (−4.9) 233 (93.2)
Table 3
Mean age, percentage distal forearm BMD change over seven years, number of deaths and mortality rates in men and women and within groups of BMD change based
on least significant change (LSC) = 2%. 1: BMD gain or BMD loss of < 1× LSC, 2: BMD loss between 1× and 2× LSC, 3: BMD loss of > 2× LSC. Crude mortality
rates (MR) are given as number of deaths per 1000 person years (py). BMD values for total hip by DEXA in Tromsø 5 presented as g/cm2 is given for comparison.
Women N Mean age (SD) Mean BMD change % (SD) Deaths
N
MR per 1000 py Mean BMD total hip Tromsø 5 (SD)
All 1725 62.4 (6.2) −4.8 (6.7) 756 31.8 0.875 (0.135)
1 Positive or unchanged 548 61.9 (6.3) 1.9 (5.0) 224 29.4 0.902 (0.144)
2 1× LSC to 2× LSC BMD loss 261 62.2 (6.2) −3.0 (0.6) 99 26.8 0.918 (0.132)
3 > 2× LSC BMD loss 916 62.8 (6.1) −9.4 (4.5) 433 34.9 0.846 (0.123)
Normal BMD 531 59.2 (5.7) −4.2 (4.8) 151 19.0 0.968 (0.128)
1 Positive or unchanged 187 58.9 (5.7) 0.4 (2.0) 50 17.6 1.003 (0.129)
2 1× LSC to 2× LSC BMD loss 106 59.6 (6.0) −3.0 (0.6) 24 15.0 0.988 (0.125)
3 > 2× LSC BMD loss 238 59.2 (5.7) −8.3 (3.8) 77 22.0 0.931 (0.120)
Low BMD 1194 63.8 (5.9) −5.1 (7.3) 605 38.3 0.831 (0.115)
1 Positive or unchanged 361 63.4 (6.1) 2.7 (5.8) 174 36.3 0.847 (0.120)
2 1× LSC to 2× LSC BMD loss 155 64.0 (5.7) −3.0 (0.6) 75 35.8 0.868 (0.114)
3 > 2× LSC BMD loss 678 64.0 (5.8) −9.7 (4.6) 356 39.9 0.815 (0.109)
Men N Mean age (SD) Mean BMD change % (SD) Deaths
N
MR per 1000 py Mean BMD total hip Tromsø 5 (SD)
All 1879 61.7 (6.0) −3.2 (3.9) 1001 42.3 1.010 (0.140)
1 Positive or unchanged 815 60.2 (5.8) −0.2 (1.8) 362 33.1 1.050 (0.134)
2 1× LSC to 2× LSC BMD loss 431 61.8 (5.9) −2.9 (0.6) 230 41.9 1.018 (0.127)
3 > 2× LSC BMD loss 633 63.7 (5.9) −7.3 (3.4) 409 56.5 0.950 (0.135)
Normal BMD 1101 60.4 (5.8) −2.5 (3.2) 496 34.0 1.058 (0.127)
1 Positive or unchanged 561 59.3 (5.5) −0.3 (1.4) 213 27.2 1.082 (0.125)
2 1× LSC to 2× LSC BMD loss 280 60.9 (6.0) −2.8 (0.6) 128 34.8 1.055 (0.115)
3 > 2× LSC BMD loss 260 62.2 (5.6) −6.9 (3.2) 155 50.4 1.012 (0.129)
Low BMD 778 63.6 (5.9) −4.2 (4.5) 505 55.6 0.936 (0.126)
1 Positive or unchanged 254 62.1 (5.9) 0.1 (2.5) 149 47.8 0.976 (0.126)
2 1× LSC to 2× LSC BMD loss 151 63.4 (5.4) −3.0 (0.6) 102 56.5 0.949 (0.120)
3 > 2× LSC BMD loss 373 64.7 (5.9) −7.6 (3.6) 254 61.1 0.903 (0.119)
LSC = Least significant change, defined as 2% negative change between measurements. MR = Mortality rate. Py = Person years.
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3.1. Potential non-response bias
The group of participants in Tromsø 4 who did not attend BMD-
testing in Tromsø 5 (and were therefore not eligible for this study) were
older, had a higher prevalence of osteoporosis, a higher percentage of
chronic diseases and poorer self-rated health compared to those who
participated in both Tromsø 4 and Tromsø 5 and the subgroup of these
which was our study sample (Table 1). Furthermore, a higher percen-
tage of non-participants died across all baseline BMD ranges, also when
excluding those who died before Tromsø 5.
4. Discussion
In this study, we examined the association between BMD loss in the
distal forearm and mortality in the general population of Tromsø,
Norway. We found no association between BMD loss and mortality in
women, regardless of baseline BMD. In men with normal BMD at
baseline, a large reduction in BMD of > 4% over seven years was
associated with significantly increased mortality compared to men with
an unchanged or increased BMD. No associations between BMD loss
and mortality were found in those with low BMD at baseline.
This is somewhat in contrast with the results of previous studies
from the US and Australia that found a statistically significant asso-
ciation between bone loss and mortality in women as well as in men
[33,34]. Also, in the US Study of Osteoporotic Fractures, the association
between bone loss and mortality did not depend on baseline BMD [33]
as we found in our study. Results from a Korean study found similar
results to ours, namely that the association between bone loss and
mortality was most pronounced in men [35].
Although we observed the highest mortality rates among those with
the largest bone loss, differences between groups of BMD change were
not statistically significant in those with low baseline BMD and there
was no linear relationship between rate of bone loss and mortality.
There are some methodological differences between our study and the
abovementioned studies to be discussed. While the intervals between
baseline- and follow-up measurements were comparable (~5–6 years vs
Table 4
Hazard ratios (HR) with 95% confidence intervals (CI) of mortality for 7-year BMD change in persons with normal and low BMD during 17 years mortality follow-up.
Models 1–3 progressively adjusted for age and lifestyle- and health-related covariates. Women and men analyzed separately with BMD change group 1 (positive or no
change) as reference.⁎
Women model adjusted for BMD change All women N = 1725 Normal N = 531 Low N = 1194
Group 1–3 HR 95% CI HR 95% CI HR 95% CI
1: Attained age, baseline BMD 1 1.00 – – 1.00 – – 1.00 – –
2 0.89 0.70 1.12 0.75 0.46 1.23 0.95 0.72 1.25
3 1.12 0.95 1.31 1.34 0.95 1.95 1.08 0.90 1.29
2: 1 + Use of AODs, BMI change, HRT, years since menopause 1 1.00 – – 1.00 – – 1.00 – –
2 0.94 0.74 1.19 0.81 0.49 1.34 1.00 0.76 1.32
3 1.10 0.93 1.29 1.34 0.93 1.95 1.05 0.88 1.27
3: 2 + Physical activity level, BMI, smoking status, level of education, self-reported
health, chronic diseases
1 1.00 – – 1.00 – – 1.00 – –
2 0.96 0.75 1.23 0.84 0.50 1.42 1.00 0.76 1.33
3 1.10 0.93 1.31 1.41 0.94 2.12 1.04 0.86 1.25
Men model adjusted for BMD change All men N = 1879 Normal N = 1101 Low N = 778
Group 1–3 HR 95% CI HR 95% CI HR 95% CI
1: Attained age, baseline BMD 1.00 – – 1.00 – – 1.00 – –
2 1.08 0.92 1.28 1.14 0.91 1.41 0.98 0.76 1.27
3 ⁎1.23 1.07 1.28 ⁎1.57 1.28 1.94 0.97 0.79 1.20
2: 1 + Use of AODs, BMI change 1 1.00 – – 1.00 – – 1.00 – –
2 1.07 0.91 1.27 1.14 0.92 1.42 0.96 0.74 1.24
3 ⁎1.20 1.03 1.39 ⁎1.53 1.24 1.88 0.95 0.78 1.17
3: 2 + Physical activity level, BMI, smoking status, level of education, self-reported health,
chronic diseases
1 1.00 – – 1.00 – – 1.00 – –
2 1.06 0.90 1.25 1.13 0.90 1.42 0.97 0.74 1.26
3 1.13 0.97 1.31 ⁎1.50 1.21 1.87 0.91 0.74 1.13
Abbreviations: AOD = anti-osteoporosis drug, BMD = bone mineral density, BMI = body mass index, HRT = hormone replacement therapy.
⁎ Statistically significant values (p < 0.05).
Fig. 2. Mortality hazard ratios (HR) with 95% confidence intervals across the range of percent seven-year change in distal forearm BMD in women and men with
normal BMD (short-dashed line) and low BMD (solid line) at baseline. No BMD change is the reference level. Histogram illustrates the population distribution.
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7 years in our study), their study populations were older than ours with
mean ages of > 70 years compared to 62 years in our study. However,
we only found BMD loss to be associated with mortality among parti-
cipants with normal BMD at baseline and that group had the lowest
mean age. The previous studies also used measurements from weight-
bearing skeletal sites such as the spine, hip and calcaneus while we used
measurements from the non-weight-bearing distal forearm in our ana-
lyses. The rates of bone loss are therefore not comparable and the re-
sults indicate a difference in how rate of bone loss relates to mortality in
weight-bearing and non-weight-bearing bones.
The reason why we only found an association between BMD loss and
mortality in those with normal baseline BMD could be the relatively
low background mortality in this group compared to those with low
BMD. Overall, people with low BMD have a higher mortality
[13–15,22] and that could be masking any additional increase in
mortality from additional BMD loss. In women, the absolute differences
in mortality between the upper and lower groups of BMD change were
similar in those with normal and low baseline BMD while the relative
differences in mortality across groups of BMD change were higher in
the group with normal BMD at baseline in both genders and especially
in men (not adjusted for age). Although the women with normal
baseline BMD and the largest BMD loss had the highest HR (1.41 in the
fully adjusted model) that were comparable to that of the men
(HR = 1.50), the association between BMD loss and mortality did not
reach statistical significance due to wide CIs, indicating a very het-
erogeneous group. The corresponding male group had twice the sample
size of the women which could explain why the association between
BMD loss and mortality reached statistical significance only in men
with normal BMD at baseline.
A possible explanation for why we only found an association be-
tween BMD loss and mortality in those with normal baseline BMD is
that it is not actually the change in BMD which explains mortality, but
rather the latest BMD measurement. Based on our results, the rate of
bone loss appears less predictive of mortality when BMD is already in
the osteopenic or osteoporotic range. A large reduction in BMD from a
point of “normal” values would cause a faster approach to an osteo-
penic and osteoporotic BMD range and an associated increase in mor-
tality. However, it is also possible that our population of participants
with low BMD from Tromsø 4, who chose to return for testing in
Tromsø 5, is a particularly healthy or resilient selection, as Emaus et al.
have pointed out earlier [25]. Participants who only attended Tromsø 4
reported more chronic diseases, poorer health and had a higher death
rate than those who returned for Tromsø 5, suggesting that our popu-
lation represent a somewhat healthier selection that might not be re-
presentative for the average person with osteopenia or osteoporosis.
In women with normal baseline BMD, those with a moderate BMD
loss of 2–4% (group 2) had the lowest mortality. Women experience a
larger reduction in BMD during- and up to 10 years following meno-
pause due to the natural change in estrogen production [23,41,42]. The
fact that a higher rate of bone loss is part of the normal ageing process
in women, could explain why the group of women who experienced a
moderate reduction in BMD had the lowest mortality risk and not the
group who experienced no change or an increase in BMD as we found in
men. Mean BMD loss in women over seven years was −4.8% and varied
little across age groups, meaning that group 2 had a smaller BMD loss
than the average woman in our population, unlike the men who had a
mean BMD loss of −3. 2%. The men's average BMD loss was also much
smaller in the younger men than in the older. The women in our study
who had unchanged or increased BMD used AODs and HRT more fre-
quently than those with a BMD reduction, also in the group with normal
baseline BMD. It indicates that these women might be of poorer health
since treatment had been initiated. AODs and HRT is also not without
side effects [43]. The fully adjusted models included use of AODs and
HRT as current, previous and never, and cessation between Tromsø 4
and Tromsø 5, but this information might not be sufficient to account
for the entire effect they have on BMD change and mortality. These
variables were also self-reported and can be subject to recall bias,
particularly the time of start or cessation [44].
Individuals who are eligible for BMD screening are often identified
due to a previous fragility fracture or the presence of established risk
factors [45]. Most people with normal BMD are not in the target group
for BMD screening, hence repeated measurements to monitor BMD
change is not likely achievable, nor advisable for this group. According
to our results, the overall impression is that BMD change in the distal
forearm does not have a strong predictive value in assessing mortality.
This study included men and postmenopausal women and is
therefore not generalizable to changes in BMD that occur before, during
or directly after menopause. We excluded women up to 5 years post
menopause to remove the main effect of menopause on bone loss and
adjusted the statistical models for years since menopause. A study on
BMD changes at different measurement sites found that accelerated
bone loss at the distal forearm persisted at the same rate throughout life
after menopause while BMD at the hip and lumbar spine show more
variation [24]. Thus, we do not suspect menopause to represent a
substantial source of bias in our results.
Strengths of this study include the population-based design with a
large sample size, standardized objective measures of BMD using the
same devices at both measurements, information on a large number of
potential confounders including measured weight and height and self-
reported lifestyle and use of medication, and a long follow-up period of
17 years with updated time of death until October 2018. The popula-
tion in the present study consists of people living in both urban and
rural areas and the study had a high attendance rate (78% in Tromsø 4
and 86% in Tromsø 5).
The study also has some limitations. BMD was measured using a
technique (SXA) that is no longer the standard method for measuring
BMD. However, comparing the precision of BMD measurements of the
forearm using SXA, and the now more commonly used DXA (dual x-ray
absorptiometry) in a population based health survey in northern
Trøndelag in Norway (HUNT), precision was found to be better for SXA
measurements than DXA [46]. It should therefore be considered a valid
and solid measurement in this type of research were the aim was to
assess BMD changes in the distal forearm specifically.
BMD is most commonly measured in the lumbar spine and proximal
femur, and sometimes in distal forearm [47]. It has been suggested that
natural bone loss might occur earlier in distal, non-weight bearing areas
like the distal forearm, than in central areas like the proximal femur or
spine [48] and the rate of bone loss appears to be site-specific [24]. Our
results therefore represent BMD changes in the distal forearm only, not
BMD changes in general since bone loss can occur later in the hip or
spine region and changes here could have a stronger or weaker asso-
ciation with mortality due to the fact that these are weight bearing sites.
5. Conclusion
In this population-based study, we found that BMD loss in the distal
forearm was associated with increased mortality in men with normal
BMD at baseline, but not in women. While the highest mortality rates
were found in those with the largest BMD loss, there was no clear as-
sociation between BMD loss and mortality in those with low BMD in the
form of osteopenia or osteoporosis at baseline. Our findings contribute
to a further understanding of distribution of bone loss in the distal
forearm and its potential association with mortality.
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